Revive Therapeutics (RVVTF) Enters the Danger Zone.
What Danger You Ask?
Danger #1, the FDA doesn't like the data, and you own the stock.
Ehave, Inc. Announces its KetaDASH Mobile Unit Delivered to Miami Beach.
MIAMI, June 03, 2022 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced...
Could Bucillamine be the Key to Preventing Lockdowns in Places Like North Korea?
Revive Therapeutics Nears FDA-EUA Approval or Non-approval, for Bucillamine its Novel Anti-inflammatory and Antioxidant. Bucillamine 'Boosts' Glutathione, a Natural Substance Found...
Cybin (CYBN) and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s...
- Preliminary data confirm Flow's ability to successfully measure neuro-effect of ketamine over 10 days -
- Results to...
Revive Therapeutics (RVVTF) Moves a Step Closer to FDA Verdict for Its Novel Covid...
Two Binary Events Directly Ahead.
As in Months Away, not Years. Share Price up 76% During April.
Revive Therapeutics (RVVTF, RVV): Updates and News Archive.
Recent Headlines
(See FDA Filing Submission at Bottom)
LIVE QUOTE
Revive Therapeutics (RVVTF) Provides Update of Psilocybin Pharmaceutical Programs
IRB approval to initiate Phase 2 study for methamphetamine abuse disordersAdvancing psilocybin oral thin film, microneedle patch and biosynthesis programs
Ehave’s Mobile Ketamine Clinic, Rolling into Town.
Longer term, Ehave's (EHVVF) performance has been a quite a disappointment. Investors grew impatient for the launch...
Coming This Monday..
Microdose's Wonderland: Miami Conference to be held at the Adrienne Arsht Center for the Performing Arts in Miami, FL on November...
Revive Therapeutics (RVVTF, RVV.CN) in Discussions to Secure Supply of 5 Billion Bucillamine Tablets.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
Not wanting to be caught...
Latest article
Adding Quantum Pharmaceutical (QNTM) $4.10 to Reverse Split Stock Watch List.
119% Gain Post Split
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value...
